Injection device and method for unlocking the operation of an injection device - Patents.com

The injection device uses an electronic unit and electrical sensor to ensure compatible drug container use, addressing cross-use challenges and enhancing safety and usability for patients with chronic diseases.

JP2024542077APending Publication Date: 2024-11-13SANOFI SA(FR)
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024526549
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-03
Filing Date
2022-11-01
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Existing injection devices face challenges in preventing unintentional cross-use of interchangeable drug containers, requiring complex mechanical redesigns and posing safety risks for patients with chronic diseases like diabetes, who may have impaired vision and require easy-to-use devices.

Method used

An injection device with an electronic unit and electrical sensor system that detects an electrical identifier on the drug container, ensuring compatibility through contactless detection, allowing only compatible drug containers to be used by activating or deactivating interlocks based on identifier matching.

Benefits of technology

Ensures patient safety by preventing misuse of drug containers, maintaining device usability, and simplifying manufacturing by avoiding mechanical redesigns, while allowing easy integration into existing devices.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542077000001_ABST
    Figure 2024542077000001_ABST
Patent Text Reader

Abstract

The present disclosure relates to an injection device and a method for unlocking the operation of an injection device. The injection device comprises: a housing (11) of elongated shape extending along a longitudinal direction (z), the housing (11) comprising a distal housing component (12) and a proximal housing component (14), the distal housing component (12) configured to accommodate a medicament container (30), the proximal housing component (14) configured to accommodate or support a drive mechanism (8) operatively engaged with the medicament container (30) for expelling or drawing a dose of the medicament (4) from the medicament container (30); the drive mechanism (8) operatively engaged with the medicament container (30); an electronic unit (70) coupled to the drive mechanism (8); and an electrical sensor (150) provided at or near a distal end of the proximal housing component (14), electrically connected to the electronic unit (70), and configured for contactlessly detecting an electrical identifier (50) provided on or in one of the medicament container (30) and the distal housing component (12).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to an injection device, such as a pen injector, and a method for unlocking the operation of the injection device, for example by reading or capturing an electrical or electronic identifier provided on or associated with a medication container. In a further aspect, the present disclosure relates to a method for unlocking the operation of an injection device. [Background technology]

[0002] Drug delivery devices for setting and dispensing single or multiple doses of liquid medication are per se widely known in the art. Typically, such devices have substantially the same purpose as a common syringe.

[0003] Drug delivery devices such as pen-type injectors must meet several user-specific requirements. For example, in the case of patients with chronic diseases such as diabetes, the patient may be physically frail and may also have impaired vision. Therefore, a suitable drug delivery device specifically intended for home medicines must be robust in construction and should be easy to use. Furthermore, the operation and general handling of the device and its components should be straightforward and easily understandable. Such an injection device should set and subsequently dispense doses of variable sized medications. Furthermore, the dose setting procedure as well as the dose dispensing procedure must be simple to operate and clear.

[0004] Patients with certain diseases may require that a certain amount of medication be injected via a syringe pen or infused via a pump.

[0005] Some drug delivery or injection devices select a variable size dose of drug and inject a pre-set dose, while other injection devices set a fixed dose and dispense it, where the amount of drug to be injected according to a given prescription schedule is always the same and does not or cannot be changed over time.

[0006] Some injection devices are implemented as reusable injection devices, where the user replaces a drug container such as a cartridge, while other injection devices are implemented as disposable injection devices, where the intention is to discard the entire injection device when the contents, i.e. the drug, have been used up.

[0007] In the case of a reusable injection device, the drug container, i.e. cartridge, must be replaced when the drug is exhausted. Here, the drug container, e.g. a glass cartridge filled with drug, must be replaced. Some primary drug containers, e.g. in the form of a drug-filled cartridge, are pre-assembled in a housing component of the injection device, such as a cartridge holder.

[0008] In any case, in the case of a reusable device, it should be ensured that only dedicated drug containers or dedicated housing components pre-assembled with such drug containers can be used with dedicated drive mechanisms of the injection device.

[0009] Typically, a wide variety of primary drug containers may be provided, differing in fill volume or drug substance or concentration. When drug containers are exchanged, it must be ensured that an injection device or drive mechanism can only be used in conjunction with dedicated drug containers intended for use with such a particular type of injection device or drive mechanism. Unintended cross-use of mismatched pairs of drug containers and drive mechanisms or injection devices must be avoided.

[0010] Some approaches have proposed to mechanically code the primary container, e.g. the drug container and / or the cartridge holder with such drug container, in order to prevent unintended mechanical coupling to a mismatched drive mechanism or a mismatched injection device. Such a solution requires redesigning each mechanical component of the injection device. Providing a wide variety of different mechanically coded housing components is very complicated in terms of injection device manufacturing and manufacturing logistics. Summary of the Invention [Problem to be solved by the invention]

[0011] It is therefore intended to provide an improved injection device and a method of operating the injection device, which aims to improve patient safety and prevent unintentional cross-use of interchangeable drug containers with the injection device. The solution aims to avoid mechanical redesign of housing components of current injection devices. It is desirable to provide a solution that can be easily incorporated into current injection devices or injection systems. The solution should be easily applicable to different demands or different scenarios of use of the injection device. [Means for solving the problem]

[0012] In one aspect, an injection device for injecting a dose of a medicament is provided. The injection device includes a housing with an elongated shape extending along a longitudinal direction (z). The housing includes a distal housing component, e.g., shown as a cartridge holder, and a proximal housing component, also shown as a body. The distal housing component is configured to accommodate a medicament container. The proximal housing component is configured to accommodate or support a drive mechanism that operably engages with the medicament container to eject or withdraw a dose of the medicament from the medicament container. The distal housing component includes a distal end that faces away from the proximal housing component. The distal end of the distal housing component typically comprises or is coupled to an injection needle to pierce or puncture a biological tissue to inject the medicament.

[0013] The injection device further includes a drive mechanism disposed or assembled to the proximal housing component and configured to operatively engage the medicament container. Typically, the drive mechanism includes a piston rod configured to apply a distal motive force to a stopper or bung of the medicament container to expel the liquid medicament from the medicament container.

[0014] The injection device further includes an electronic unit coupled to the drive mechanism. The injection device also includes an electrical sensor provided at or near the distal end of the proximal housing component. The electrical sensor is electrically connected to the electronic unit and configured to detect an electrical identifier provided on or in one of the drug container and the distal housing component. The electronic unit can be embedded in or on the injection device. The electronic unit can be located inside the housing of the injection device and can be permanently coupled to or assembled inside the injection device. In some examples, the electronic unit is an embedded electronic unit that is integrated into the injection device or its drive mechanism. The electrical connection between the electrical sensor and the electronic unit as well as any other electrical connection mentioned herein can be implemented as a wired connection.

[0015] Typically, by electrical or electronic interaction between the electrical sensor and the electrical identifier, information indicative of the identifier and / or identifier information indicative of the medication container can be captured, read and / or processed by an electronic unit of the injection device.

[0016] The electrical sensor is configured to non-contact detect the presence and / or type of electrical identifier, which may be provided on or in one of the medication container and the distal housing component, among others. Such non-contact electrical detection may include inductive coupling between the electrical sensor and the electrical identifier. Non-contact detection of the electrical identifier by the electrical sensor is beneficial in that the proximal and distal housing components may not have electrical contact pins or pads that provide an electrical connection between the distal and proximal housing components.

[0017] Typically, the electrical identifier may be implemented as an electronic identifier, an electronic passive identifier, and / or an inductive identifier.

[0018] Furthermore, the non-contact, e.g., inductive coupling between the electrical identifier and the electrical sensor provides and enables a very versatile design of the proximal and distal housing components. The electrical sensor and the electrical identifier can be invisible from the outside of the housing. They may be located inside the housing, e.g., inside the sidewall of the housing, or may be embedded in the sidewall of the respective housing component. In this way, a very long-lasting, robust and reliable implementation of the electrical sensor and the electrical identifier can be provided.

[0019] The electrical identifier provides electrical coding of at least one of the distal housing component and the medicament container. Different types of distal housing components and / or medicament containers can be distinguished by electrically or electronically measurable parameters of the respective electrical identifiers. By implementing an electrically coded medicament container or distal housing component, the mechanical interlocking interface between the distal housing component and the proximal housing component can remain constant for all available types of various housing components and / or medicament containers.

[0020] According to a further example, the drive mechanism includes at least one interlock configured to disable at least one of the dose setting and the dose dispensing, where the at least one interlock can be at least temporarily deactivated based on a signal obtained from the electric sensor, when the information or data indicative of the identifier matches associated data of a given drug container, e.g. stored in the electronic unit, the drive mechanism is unlocked and the respective drug container can be used with the drive mechanism of the injection device.

[0021] In some instances where the electrical identifier provided on or in one of the distal housing component and the medication container does not match the drive mechanism and information obtained from the electrical identifier by the electrical sensor does not match the associated data for a given medication container, the interlock remains activated and use of the injection device, for example for setting and / or administering a dose, is prevented or blocked.

[0022] The signal processing can be performed by the electronic unit of the injection device, for example to keep the interlock activated when the electrical identifier does not match a predetermined requirement, demand or usage scenario. The electronic unit can keep the at least one interlock activated, so that the setting of a dose and / or the administration of a medication is and remains disabled. When the data obtained from the electrical identifier matches a predetermined requirement, demand or usage scenario, the electronic unit can at least temporarily deactivate the at least one interlock, and the drive mechanism becomes unlocked to effect the setting of a dose and / or the injection of a medication.

[0023] According to a further example, the electronic unit of the injection device is operable to control at least one interlock based on a signal received from the electrical sensor: if the signal received from the electrical sensor indicates the presence of a first type of drug container and the electronic unit is embedded in a second type of drive mechanism generally incompatible with the first type of drug container, the electronic unit is operable to activate the interlock to prevent at least one of setting and injection of a dose of drug.

[0024] In a further example, the proximal end of the distal housing component is removably connectable to the distal end of the proximal housing component. By removing or disconnecting the distal housing component from the proximal housing component, the drug container, e.g., a drug-filled cartridge, can be replaced as needed.

[0025] Additionally, the distal housing component includes a mating end for releasably mating with a complementary mating end of the proximal housing component. Typically, the mating end of the distal housing component is provided at a proximal end of the distal housing component. Typically, the mating end of the proximal housing component is provided at a distal end of the proximal housing component.

[0026] Typically, and by way of further example, one of the connecting end of the distal housing component and the connecting end of the proximal housing component includes an insert portion configured to be inserted into a complementary receptacle provided on the other of the connecting end of the distal housing component and the connecting end of the proximal housing component.

[0027] In this manner, the insert can be received inside the receptacle by a longitudinal insertion movement. When the final assembly configuration is reached, the insert is at least partially, if not entirely, received inside the receptacle, where the side walls of the insert are located inside the side walls of the receptacle. Thus, the insert and the receptacle form a nested or interdigitated configuration of distal and proximal housing components. Here, the electronic sensor provided at the distal end of the proximal housing component and the electrical identifier provided at the proximal end of the distal housing component can overlap longitudinally and / or radially to cooperate or interact in a contactless manner.

[0028] Typically, the drive mechanism provided on or in the proximal housing component is resettable: when the housing components are uncoupled, the drive mechanism typically undergoes a reset action so that the injection device can be set to an initial configuration after inserting a new medicament container into the distal housing component and when the distal housing component is recoupled with the proximal housing component.

[0029] According to further examples, the electrical identifier is disposed on or secured to one of the connecting end of the distal housing component and the proximal end of the medicament container. The electrical identifier can be provided on an outer surface of the connecting end of the distal housing component or an outer surface of the proximal end of the medicament container. In some examples, the electrical identifier is disposed on one of an inner surface of the connecting end of the distal housing component and an inner surface of a sidewall of the medicament container. It may be located outside of a fill volume of the medicament container that is intended to be filled with the injectable medicament.

[0030] In some examples, the electrical identifier is embedded inside the sidewall of the distal housing component. In this manner, the electrical identifier can be invisibly incorporated inside the structure of the housing component. In some examples, the electrical identifier includes a conductive structure, such as a helically wound wire, insert molded into the injection molded sidewall of the distal housing component.

[0031] In further examples, the electrical sensor is disposed on or in the coupling end of the proximal housing component. The electrical sensor can be provided on an exterior surface of the sidewall of the proximal housing component or an interior surface of the sidewall of the proximal housing component. In some examples, the electrical sensor is disposed or embedded inside the sidewall of the proximal housing component. Again, the electrical sensor can include a helically wound conductive wire embedded or embedded in the sidewall of the proximal housing component. This can be insert molded into the injection molded proximal housing component.

[0032] Generally, there are numerous ways to implement or provide the spirally wound wire of one of the electrical identifier and electrical detector in or on at least one sidewall of the distal or proximal housing component, In some examples, the spirally wound wire is insert molded into the sidewall, for example, by a two or more color injection molding process in which the housing sidewall is formed or constructed.

[0033] In other examples, the helically wound wire is wound or coiled on the outer surface of the barrel. The barrel with the helically wound wire is then inserted into a receptacle of a complementary distal or proximal housing component. The barrel is fastened to the respective housing component, for example, with an adhesive or by a press fit. In either case, the helically wound wire is located between the outer surface of the body and the inner surface of the sidewall of the respective housing component. In some examples where the electrical identifier is provided on the outer surface of the distal housing component, the electrical sensor is provided on the outer surface of the proximal housing component or is located on the inner surface of the sidewall of the proximal housing component. In such configurations, the electrical sensor is not provided on the inner surface of the proximal housing component. In other examples, the electrical identifier is located on the inner surface of the sidewall of the distal housing component or the electrical identifier is embedded on the inner surface of the sidewall of the distal housing component, and the electrical sensor can be provided on one of the inner surface of the sidewall of the proximal housing component and the outer surface of the sidewall of the proximal housing component, or can be located on the inner surface of the sidewall of the proximal housing component.

[0034] Typically, the material of the sidewall of the proximal housing component and / or the material of the sidewall of the distal housing component are electrically insulating. The proximal housing component and / or the distal housing component may comprise an injection molded plastic material. In this manner, when the proximal and distal housing components are in a final assembly configuration, the material of the sidewall of each housing component provides electrical insulation between the electrical sensor and the electrical identifier.

[0035] In some examples, the electrical identifier is located on the medication container. In other examples, the electrical identifier is located on the distal housing component, which is pre-assembled with the medication container, where the medication container is non-removably connectable to the distal housing component. Typically, the distal housing component is removably connectable to and / or removably securable to the proximal housing component.

[0036] According to a further example, the electrical identifier includes an inductive or solenoidal coil having a coil axis extending substantially parallel to a longitudinal direction of the housing. The coil may include a number of helical windings. The number of windings may dictate a distinct inductive response of the coil when excited by a magnetic or electromagnetic field provided, for example, by an electrical sensor.

[0037] The induction coil can extend around the sidewall of the distal housing component and / or around the sidewall of the drug container. In some examples, the drug container includes a tubular shaped barrel, for example made from a glass material. The induction coil of the electrical identifier can extend around an outer or inner circumference of the respective tubular shaped structures of the drug container and / or the distal housing component. The induction coil can surround or encircle the sidewall of the drug container and / or the sidewall of the distal housing component.

[0038] According to a further example, the electrical identifier includes a levitation coil, where the induction coil is essentially closed. The electrical identifier may be devoid of external contact pins or contact pads. This allows for very simple and straightforward fastening or embedding of the electrical identifier onto or into the distal housing component and the medication container.

[0039] With an electrical identifier that has no contact pads or contact pins, the electrical identifier can be positioned at any angular orientation relative to its coil axis, which greatly simplifies and eases the method of assembly of the electrical identifier onto or into the distal housing component and / or medication container.

[0040] According to a further example, the induction coil is provided on a flexible substrate configured to be attached or disposed on one of the tubular side walls of the distal housing component and the drug container. The flexible substrate can include a bendable or pliable foil by which the induction coil can be attached to at least one of the tubular side walls of the distal housing component and the drug container. The induction coil can include printed conductors attached to the flexible substrate by printing. The printed conductive structures on the flexible substrate can be manufactured in large quantities at reasonable or low cost. This allows the use of electrical identifiers in a mass manufacturing environment, allowing a large number of housing components or drug containers to be electrically and / or electronically coded. Such housing components or drug containers can be configured or implemented as disposable components, i.e. components intended to be discarded after use.

[0041] According to a further example, the flexible substrate includes an adhesive layer for adhesively attaching the electrical identifier to a sidewall of one of the distal housing component and the medication container. The adhesive layer and the inductive coil can be provided on the same or opposite sides of the flexible substrate. In either case, the adhesive layer can provide a durable, non-removable coupling of the electrical identifier on one of the distal housing component and the medication container.

[0042] The substrate can form or include a label configured to be attached to a sidewall of the drug container or distal housing component. The label can include printed information indicating the drug or use of the drug. Here, the induction coil can be incorporated into the label and appearance of the drug container or the distal housing component can remain visually unaffected by the coil implementation.

[0043] According to a further example, a passive electronic identifier is a non-energized electronic identifier that lacks a persistent source of electrical energy, which allows for reduced manufacturing costs and storage space for implementing the identifier on the medication container or distal housing component. A passive or non-energized electronic identifier can be manufactured in large quantities at low or affordable cost. It can be implemented or configured as a disposable electronic identifier.

[0044] According to further examples, the passive electronic identifier includes a microchip and an antenna. The antenna is configured to harvest electrical energy from a surrounding electromagnetic field. The coil or solenoid of the inductive identifier can be implemented as internal; or vice versa. In some examples, the passive electronic identifier is implemented as a Near Field Communication (NFC) tag. In some examples, the passive electronic identifier includes a passive RFID tag. Furthermore, in some examples, the passive electronic identifier includes a Near Field Communication tag configured to communicate with an electrical sensor implemented as a corresponding Near Field Communication interface of the electronic unit.

[0045] According to a further example, the electronic identifier includes non-volatile memory that stores at least one of the following: a drug name, a drug manufacturing date, a drug expiration date, a drug lot number, or a unique drug container ID. In this manner, a wide variety of drug-related data can be stored in or by the identifier and retrieved or extracted through reading of the identifier.

[0046] According to a further example, the non-volatile memory of the electrical or electronic identifier is at least one of erasable and / or writable by the electrical sensor. In this way, the non-volatile memory of the passive electronic identifier can be reconfigured. The non-volatile memory can be provided with a verification flag indicating whether the respective electronic identifier has previously undergone a read or write operation. By providing an erasable or writable non-volatile memory, such a read or invalidation flag can be set or reconfigured when the non-volatile memory is read or read by the electrical sensor for the first time or repeatedly. Here, the electrical sensor can be implemented as an inductive transmission device.

[0047] In this manner, patient safety may be enhanced, for example, by preventing multiple consecutive uses of the same medication container with the same or different injection devices. In particular, medication containers with unique medication container IDs may be marked as deactivated, such that misuse of the container, e.g., unintended substitution of a container, is somewhat more difficult to achieve, since such unauthorized containers would then be inoperable to deactivate the interlock of the injection device.

[0048] According to a further example, the electrical sensor includes an inductive or solenoid coil having a coil axis extending substantially parallel to the longitudinal direction (z) of the housing. In this example, the distal and proximal housing components are finally assembled into a final assembly configuration in which the drug container is disposed inside the housing, and the inductive coil of the electrical identifier and the conductive coil of the electrical sensor are aligned and extend coaxially relative to each other. In this manner, a longitudinal and / or radial mechanically non-contacting overlap can be provided between the inductive coils of the electrical identifier and the electrical sensor, respectively.

[0049] This results in a distinct inductive coupling between the respective induction coils, thereby allowing detection of a measurable characteristic of the electrical identifier, such as a characteristic analog or digital response, e.g., a characteristic resonant frequency or other inductively measurable parameter.

[0050] The inductive coil of the electrical sensor can include multiple helical windings extending around the inner or outer circumference of the tubular sidewall of the proximal housing component. The coil of the electrical sensor can be disposed on, in, or inside the distal coupling end of the proximal housing component. In the final assembly configuration of the proximal and distal housing components, the inductive coil of the electrical sensor can surround or encircle the inductive coil of the electrical identifier; or vice versa.

[0051] The inductive coil of the electrical sensor includes a first end with a first connector and a second end opposite the first end with a second connector, the first and second connectors being in electrical communication with the electronic unit.

[0052] In some examples, the induction coil of the electrical sensor and the induction coil of the electrical identifier overlap with respect to a longitudinal direction of the housing. The coils can be oriented and / or positioned coaxially with respect to one another when the respective housing components are coupled or assembled with one another. When the induction coils of the electrical sensor and the electrical identifier overlap with respect to a longitudinal direction, the diameter of one coil is smaller than the diameter of the other coil to allow for a longitudinally nested and concentric coil arrangement.

[0053] In other examples, the induction coil of the electrical sensor and the induction coil of the electrical identifier are arranged in a longitudinally non-overlapping configuration. Again, the coils can be coaxially arranged and / or oriented with respect to one another, but can include substantially equal diameters. Here, the induction coil of the electrical identifier can be longitudinally offset from the induction coil of the electrical detector when the distal and proximal housing components are in an assembly configuration with one another, and when the distal and proximal housing components are coupled to one another. In some examples, the induction coil of the electrical identifier can be longitudinally adjacent to the induction coil of the electrical detector, with the respective coils remaining electrically insulated from one another.

[0054] In this manner, the radial dimensions of the inductively coupled coils of the electrical identifier and the electrical detector can be somewhat equal in size, thus allowing for very simple and intuitive mounting to the respective housing components.

[0055] In fact, the coils of the electrical identifier and the electrical detector may not need to overlap longitudinally to achieve inductive coupling. Inductive coupling can be achieved when the coils are spaced longitudinally apart from one another or when the respective inductive coils are longitudinally adjacent to one another, allowing greater freedom in positioning and attachment of the respective inductive coils to at least one of the distal housing component, the proximal housing component, and the medicament container.

[0056] According to a further example, the at least one interlock of the drive mechanism includes an electromechanical interlock configured to mechanically engage a first component of the injection device and a second component of the injection device. The first component is movable relative to the second component for at least one of dose setting and dose injection of the medicament. Typically, for at least one of dose setting and dose dispensing or dose injection, the at least one interlock is operable to switch between an interlock state in which the first component is movably locked to the second component and a released state in which the first component is movable relative to the second component.

[0057] In some examples, the first component is longitudinally movable relative to the second component for at least one of dose setting and dose injection. In other examples, the first component is rotatable relative to the second component for at least one of dose setting and dose injection. In the case of rotatable relative displacement between the first and second components, the axis of rotation typically extends along the longitudinal or axial direction of the housing of the injection device.

[0058] In some examples, the first component undergoes a helical movement relative to the second component for dose setting and / or dose injection of the medicament. At least one of the first and second components may belong to the drive mechanism. In some examples, both the first and second components belong to the drive mechanism of the injection device. In other examples, at least one of the first and second components is part of or forms the housing of the injection device.

[0059] Typically, in further examples, the electromechanical interlock includes an electrically implemented actuator operably engaged with the latch. In some examples, the latch is movable by the actuator along a longitudinal direction, along a radial direction, and / or along a tangential direction relative to the cylindrical or tubular geometry of the housing of the injection device. Typically, the actuator is located and / or fixed to one of the first and second components. The latch can be provided on the same component and can be mechanically engagable with the other of the first and second components to block or prevent relative movement between the first and second components when the interlock is in an interlocked state.

[0060] In some examples, the drive mechanism of the injection device includes a piston rod, a number sleeve, a drive sleeve, or a driver, and at least one of a dose dial and a trigger or a dose button. Typically, the dose dial is rotatable relative to the housing for dose setting. During dose setting, the rotational movement of the dial is transferred to a respective rotational movement of the number sleeve. Here, at least one of the dose dial and the number sleeve can be locked non-rotatably and / or non-translatably by an interlock to prevent dose setting.

[0061] For dose dispensing or dose injection, the trigger or dose button must be depressed by the user. The trigger button can be depressible relative to the dose dial, the housing, the number sleeve, or the piston rod. During dose dispensing, the driver or drive sleeve typically undergoes a rotational motion, which is transferred to a longitudinal and / or rotational motion of the piston rod. During dose injection, the number sleeve typically rotates in a direction opposite to the direction of rotation during dose setting. Here, the interlock can be operable to block the actuation or movement of the trigger, block the rotation of the driver or drive sleeve, block the rotation or movement of the piston rod, and / or block or inhibit the rotation or movement of the number sleeve.

[0062] In addition to these examples, further implementations of the interlock or electromechanical interlock are possible and contemplated, so long as the first and second components that are to lock and engage with each other undergo relative movement during at least one of dose setting and dose dispensing.

[0063] According to a further example, the drive mechanism includes at least one clutch operable to switch the drive mechanism between a dose setting mode and a dose injection or dose dispensing mode, and the at least one interlock is operably engaged with the at least one clutch to selectively disable switching of the drive mechanism from one of the dose setting mode and the dose injection mode to the other of the dose setting mode and the dose injection mode.

[0064] In some examples, the drive mechanism includes a first clutch and a second clutch. The first clutch allows the number sleeve to selectively engage with the dose dial, the driver, or the drive sleeve of the drive mechanism. In this way, the rotation of the dose dial can be transferred to the respective rotation of the number sleeve during dose setting. During dose injection, the number sleeve can be decoupled and released from the dose dial. Here, the number sleeve can be rotated in the opposite rotational direction, but the dose dial does not have to follow its rotation and remains non-rotatably locked to the housing of the injection device.

[0065] The second clutch allows the dose dial and / or number sleeve to selectively engage with a driver or drive sleeve of the drive mechanism. Further, the second clutch and / or third clutch can provide selective engagement between the driver or drive sleeve and the piston rod to move the piston rod distally exclusively during dose injection.

[0066] Generally, the drive mechanism of the injection device can be implemented in a variety of different ways. One example of a drive mechanism is disclosed, for example, in WO2004 / 078239A1, the entirety of which is incorporated herein by reference. Another example of a drive mechanism implemented with an injection device is disclosed, for example, in WO2014 / 033195A1, the entirety of which is incorporated herein by reference.

[0067] According to a further example, the at least one interlock is controlled by a processor of the electronic unit, the processor being configured to activate the at least one interlock when one or several of the following conditions are detected by the electronic unit: end of dose injection, exhaustion of contents of the drug container, lapse of a predefined time with the at least one interlock in a deactivated state, removal or insertion of the drug container from the housing, insertion of the drug container into the housing, execution of a manual reset of the drive mechanism, or lapse of a predefined time with the communication link between the short-range communication interface of the electronic unit and the identifier being deactivated.

[0068] Any further circumstances may be provided that trigger the processor to activate or deactivate the interlock. Typically, any of the above circumstances may result in automatic activation of the interlock, which effectively prevents unintended or unauthorized use of the injection device. Any of the above mentioned circumstances may be detected, for example, by at least one sensor, as further described below.

[0069] According to a further example, the injection device includes a drug container filled with a drug. The drug container is disposed inside the housing. Typically, the drug container includes a cartridge filled with a drug. The cartridge may include a tubular shaped barrel, e.g. made from a glass material. The barrel may be sealed proximally by a moveable stopper along the length of the barrel to expel the liquid drug through a distally located barrel outlet.

[0070] The distally located outlet can be sealed by a seal. The seal at the distal end of the cartridge can include a sealing disk, for example made from a rubber material and pierceable by a double-ended injection needle. The rubber seal can be fixed or assembled to the distal end of the tubular barrel by a crimped metal cap.

[0071] According to a further example, the drug container can be non-removably attached to the distal housing component. The distal housing component typically includes a tubular shaped cartridge holder shaped and configured to accommodate the drug cartridge therein. The cartridge holder can be equipped with snap features to secure the cartridge inside the cartridge holder. In this way, a pre-assembly of the cartridge holder and the cartridge can be provided that can be distributed as a product to the end consumer or patient. In such a pre-assembly, the electrical identifier can be provided on the outer surface of the distal housing component and thus on the outer surface of the cartridge holder. It can also be provided on the side wall of the drug container, i.e. on the barrel of the cartridge.

[0072] According to a further example, the electronic unit of the injection device includes at least one sensor that detects or measures the movement of at least one movable component of the injection device. The movable component of the injection device may indicate a particular device configuration or device operation. By detecting the movement or the magnitude of the movement of the movable component, the electronic unit is provided with information regarding the operational status of the injection device.

[0073] Typically, in some instances, the sensor is operable to quantitatively measure the extent of movement of the at least one movable component. The at least one sensor may be operable to measure the extent of rotation and / or the extent of longitudinal movement of the at least one movable component, for example relative to the housing of the injection device or relative to another movable component of a drive mechanism of the injection device.

[0074] Data regarding the dose size can be derived by at least one sensor, which is operable to provide an electrical signal indicative of the size of the dose actually set and / or dispensed or injected by the drive mechanism of the injection device. Typically, the electronic unit comprises a memory and a clock. In this way, the dose history or injection history can be automatically captured and stored in the memory of the electronic unit.

[0075] The electronic unit may further comprise a short-range communication interface, including a wireless communication interface based on one of the following communication standards: Bluetooth, Bluetooth low energy (BLE), Zigbee, or Wi-Fi. Typically, the short-range communication interface of the electronic unit is operable to set up a communication link with a corresponding short-range communication interface of an external electronic device. The external electronic device may be implemented as a portable electronic device such as a smartphone, a smartwatch, or a tablet computer.

[0076] In particular, by means of an optional short-range communication interface and by means of a communication link with an external electronic device, medication-related data, such as injection history, and thus injection-related data, can be synchronized with the external electronic device and transmitted to a healthcare provider for further data analysis. In this way, repeated use of the injection device can be precisely tracked and measured, and user compliance with a given prescription schedule can be monitored.

[0077] According to a further aspect, the present disclosure relates to a kit of injection devices, in particular a first type of injection device and at least a further type, e.g., a second type of injection device. The first type and the second type of injection device are differentiated by their drug or drug container. The first type of drug container can be differentiated from the second type of drug container by its size, type of drug, pharmacologic active substance, and / or concentration of pharmacologic active substance.

[0078] The first type of medicament container is configured exclusively for use with a first type of drive mechanism. The second type of medicament container is configured exclusively for use with a second type of drive mechanism. Unintended cross-use, i.e., use of a first type of medicament container with a second type of injection mechanism, should be avoided.

[0079] To that end, a first type of drug container comprises and / or is associated with an electrical identifier of a first type; a second type of drug container comprises and / or is associated with an electrical identifier of a second type. By means of the electrical identifiers the respective type of drug container can be detected, where the identifiers provide a certain coding; the first type of identifier represents a first coding; the second type of identifier represents a second coding; the different types of identifiers are detectable and / or readable by an electrical sensor.

[0080] An electrical signal generated by the electrical sensor when interacting with the electrical identifier is provided and transmitted to the electronic unit, which can identify the electrical identifier and the associated housing component or medicament container based on such electrical signal, i.e. based on the so-called detection signal. The electronic unit, in particular the processor of the electronic unit, is further configured to verify the detection signal and to at least temporarily deactivate or reactivate at least one interlock based on verification of the detection signal obtained from the electrical sensor through interaction with the electrical identifier.

[0081] The electrical identifier may represent an electronic coding or an electronically detectable coding. Such an identifier or coding allows the use of housing components that are not mechanically coded for the first and second types of injection devices. Even if a distal housing component with a first type of drug container is assembled with a proximal housing component of a second type and comprises a second type of injection device, such combination is not operable to disable or deactivate the interlock of the drive mechanism. Setting and / or injection of a dose is effectively prevented.

[0082] According to another aspect, the present disclosure relates to a method of unlocking the operation of an injection device as described above for at least one of setting or injecting a dose of a medicament. The injection device includes a housing having an elongated shape extending along a longitudinal direction. The housing includes a distal housing component and a proximal housing component. The distal housing component is configured to house or receive a medicament container as described above. The proximal housing component is configured to house or support a drive mechanism that operably engages with the medicament container to expel or withdraw a dose of the medicament from the medicament container. Typically, the injection device includes a drive mechanism disposed inside the proximal housing component.

[0083] The injection device further includes an electronic unit coupled to the drive mechanism. The injection device also includes an electrical sensor provided at or near a distal end of the proximal housing component. The electrical sensor is electrically connected to the electronic unit and configured to detect an electrical identifier provided on or in one of the medicament container and the distal housing component. A method of unlocking operation of the injection device includes detecting, by the electrical sensor, at least one of the presence and type of the electrical identifier. This detection can occur before, during, or after assembling the distal and proximal housing components together with the medicament container located inside the distal housing component.

[0084] After contactlessly detecting the electrical identifier by the electrical sensor, at least one detection signal is generated, for example by the electrical sensor. The at least one detection signal is indicative of the electrical identifier. The at least one detection signal is then transmitted to an electronic unit. The electronic unit processes or verifies the detection signal, and at least temporarily deactivates or reactivates the at least one interlock based on the verification of the detection signal.

[0085] Generally, the method of unlocking the operation is to be performed by an injection device as described above, comprising an interlock configured to disable dose setting and / or dose dispensing, in which case all the configurations, effects and benefits described above with respect to the injection device equally apply to the method of unlocking the operation of the injection device.

[0086] According to a further example, the method includes verifying the electrical identifier detection signal obtained from the electrical identifier by comparing the detection signal obtained from the electrical identifier with predefined data related to the injection device. Such predefined data may be stored in a local storage of the electronic unit. In this way, it may be determined or determined whether the electrical identifier matches the predefined data related to the injection device and whether the medication container is usable or intended to be used with the injection device.

[0087] If the acquired or captured electrical identifier-related data does not match predefined data related to the injection device, the drive mechanism is or remains actively locked by the interlock. The injection device is then effectively inoperable to set a dose of medication and / or inject a dose of medication. In a further example, the method and step of validating the identifier may include modifying the identifier. This may be particularly useful for digital implementations of the electrical identifier by its digital encoding.

[0088] Here, in some examples, the electronic unit of the injection device can be operable to read the electronic storage of the passive electronic identifier. Upon such a read operation, a read flag for each of the electronic identifiers can be set to mark the electronic identifier as currently in use or used. Repeated use of the passive electronic identifier and / or the medication container associated with the identifier can then be effectively prevented or blocked, for example, to prevent or hinder unintended and / or unauthorized use of the medication container. In that case, the capture or reading of the identifier can include an evaluation or acknowledgement of the status of the read flag provided by the electronic storage of the electronic identifier.

[0089] Alternatively, in a further example, a database request may be invoked using an external database, for example via a network connection, when an identifier provided on or associated with the medication container is read by the electrical sensor. In the database, the medication container currently in use may be marked as ready for use or not suitable for use. With such a database request, additional information may be gathered as to whether a particular medication container can be used or whether it should not be used or cannot be used with the injection device.

[0090] According to another aspect, there is provided a label attached to at least one of a housing of an injection device or a medication container configured to be inserted into a housing of an injection device. The label includes a flexible substrate comprising a conductor strip. The flexible substrate is rollable or coilable into a rolled or coiled configuration such that the conductor strip forms an inductive identifier. In the rolled or coiled configuration, the conductor strip includes a helical structure having at least one or multiple helical windings that effectively provides an inductive coil.

[0091] In some examples, the conductor strip is coated or printed on a first side of the flexible substrate. A second side of the flexible substrate comprises an adhesive, e.g., an adhesive layer for securing the substrate to at least one sidewall of a distal housing component, a proximal housing component, or a drug container of the injection device. In other examples, the adhesive and / or adhesive layer is provided on the first side, where the adhesive and the conductor strip are provided on the same side of the flexible substrate.

[0092] In some examples, the conductor strip includes a first elongated conductor strip portion and a second elongated conductor strip portion, the first elongated conductor strip portion extending at an angle relative to the length of the second elongated conductor strip portion. In some examples, the second elongated conductor strip portion extends substantially parallel to or coaxial with an axis of symmetry of the wound or coiled flexible substrate, where the second elongated conductor strip extends parallel to the coil axis of the coiled or wound flexible substrate. The first elongated conductor strip can then form a helically wound portion of the conductor strip.

[0093] In some examples, the conductor strip includes a first longitudinal end with a first contact zone and further includes a second longitudinal end with a second contact zone. The first and second contact zones include distinct sizes and / or geometric shapes, e.g., square, rectangular, round, or oval shapes, and their diameters or cross sections are larger than the diameter or cross section of the elongated conductor strip.

[0094] In a further example, when the flexible substrate is in a coiled configuration forming at least one or multiple turns or windings, the first contact zone and the second contact zone can at least partially overlap when viewed radially relative to the coil axis.

[0095] In a further example, the substrate is electrically insulating. When in the coiled or wound configuration, the substrate is located between first and second radially overlapping contact zones that are at least partially overlapping. In this manner, the first and second contact zones and the electrically insulating material located therebetween effectively form a capacitor.

[0096] The overlapping contact zones provide a capacitor together with the coiled or wound conductor strip located therebetween to form an LC circuit configured to characterize the respective label. The LC circuit itself can be characterized by the number of turns of the conductor strip and / or the capacitance of the capacitor formed by the overlapping contact zones.

[0097] By modifying the number of windings as well as the capacitance of the capacitor, a number of LC circuits of different scales can be provided, each featuring a distinct resonant frequency. In this manner, a label can be provided that is configured to be attached to the tubular body of the housing of an injection device or the tubular barrel of a drug container.

[0098] Generally, the label may also comprise a printed label portion, thus providing readable or visible information regarding the injection device or medication.

[0099] The coiled configuration of the label provides an induction coil that can be inductively coupled to an electrical detector, e.g. with a suitable induction detector or reader, such as a reader coil. Substrates with printed or coated conductive strips are suitable for very cost-effective mass manufacturing processes and are therefore attractive for labeling components of injection devices in a cost-effective and simple manner.

[0100] Electronic labels may be free of logical electronic components and semiconductor materials, which enables a very environmentally friendly implementation of electrically and / or inductively readable labels.

[0101] Generally, the scope of the present disclosure is defined by the content of the claims. The injection device is not limited to a particular embodiment or example, but includes any combination of elements of different embodiments or examples. In that case, the present disclosure encompasses any combination of claims and any technically feasible combination of the disclosed features with respect to the different examples or embodiments.

[0102] In the present context, the term "distal" or "distal end" refers to the end of the injection device that faces towards the injection site of a person or animal, and the term "proximal" or "proximal end" refers to the opposite end of the injection device that is furthest from the injection site of a person or animal.

[0103] The terms "drug" or "medicament" are used interchangeably herein to describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients or their pharma- ceutically acceptable salts or solvates, and optionally a pharma- ceutically acceptable carrier. An active pharmaceutical ingredient ("API"), in its broadest sense, is a chemical structure that has a biological effect on humans or animals. In pharmacology, drugs or medicines are used to treat, cure, prevent, or diagnose diseases or otherwise improve physical or mental well-being. Drugs or medicines can be used for a limited duration or periodically for chronic disorders.

[0104] As described below, a drug or agent may include at least one API or a combination thereof in various types of formulations for the treatment of one or more diseases. Examples of APIs may include small molecules with molecular weights of 500 Da or less, polypeptides, peptides, and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes), carbohydrates and polysaccharides, as well as nucleic acids, double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.

[0105] The drug or agent can be contained in a primary package or "drug container" adapted for use in a drug delivery device. The drug container can be, for example, a cartridge, syringe, reservoir, or other rigid or flexible vessel configured to provide a chamber suitable for storage (e.g., short-term or long-term storage) of one or more drugs. For example, in some cases, the chamber can be designed to store the drug for at least one day (e.g., from one day to at least 30 days). In some cases, the chamber can be designed to store the drug for about one month to about two years. Storage can be at room temperature (e.g., about 20° C.) or at refrigerated temperatures (e.g., from about −4° C. to about 4° C.). In some cases, the drug container can be or include a dual-chamber cartridge configured to separately store two or more components of a pharmaceutical formulation to be administered (e.g., an API and a diluent, or two different drugs), one in each chamber. In such cases, the two chambers of the dual-chamber cartridge can be configured to allow mixing between two or more components prior to and / or during administration to the human or animal body. For example, the two chambers can be configured to be in fluid communication with each other (e.g., via a conduit between the two chambers) and to allow mixing of the two components by a user, if desired, prior to administration. Alternatively or additionally, the two chambers can be configured to allow mixing upon administration of the components to the human or animal body.

[0106] The drugs or agents contained in the drug delivery devices described herein can be used for the treatment and / or prevention of many different types of medical disorders. Examples of disorders include, for example, diabetes or complications associated with diabetes, such as diabetic retinopathy, thromboembolic disorders, such as deep vein thromboembolism or pulmonary thromboembolism. Further examples of disorders are acute coronary syndromes (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis. Examples of APIs and drugs are those found in handbooks such as Rote Liste 2014 (e.g., but not limited to, main groups 12 (antidiabetic agents) or 86 (oncology agents)) and the Merck Index, 15th edition.

[0107] Examples of APIs for the treatment and / or prevention of type 1 or type 2 diabetes or complications associated with type 1 or type 2 diabetes include insulin, e.g., human insulin, or a human insulin analog or derivative, glucagon-like peptide (GLP-1), a GLP-1 analog or GLP-1 receptor agonist, analog or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharma-ceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms "analog" and "derivative" refer to a polypeptide having a molecular structure that is formally derivable from the structure of a naturally occurring peptide, e.g., the structure of human insulin, by deletion and / or replacement of at least one amino acid residue present in the naturally occurring peptide and / or by addition of at least one amino acid residue. The added and / or replaced amino acid residue can be either a codable amino acid residue or another naturally occurring residue or a purely synthetic amino acid residue. Insulin analogs are also referred to as "insulin receptor ligands". In particular, the term "derivative" refers to a polypeptide having a molecular structure formally derivable from the structure of a naturally occurring peptide, e.g., the molecular structure of human insulin in which one or more organic substituents (e.g., fatty acids) are attached to one or more of the amino acids. Optionally, one or more amino acids present in the naturally occurring peptide are deleted and / or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable ones, are added to the naturally occurring peptide.

[0108] Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin in which the proline in position B28 may be replaced by Asp, Lys, Leu, Val or Ala and in which the Lys in position B29 may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

[0109] Examples of insulin derivatives are e.g. B29-N-myristoyl-des(B30) human insulin, Lys(B29)(N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl-LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin. ; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl-des(B30) human insulin (insulin degludec, Tresiba®); B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.

[0110] Examples of GLP-1, GLP-1 analogs and GLP-1 receptor agonists are, for example, lixisenatide (Lyxumia®), exenatide (exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide produced by the salivary glands of the flathead monster), liraglutide (Victoza®), semaglutide, taspoglutide, albiglutide (Syncria®), dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023, TTP-054, langrenatide / HM-11260C (efpegrenatide). , HM-15211, CM-3, GLP-1 Erigen, ORMD-0901, NN-9423, NN-9709, NN-9924, NN-9926, NN-9927, Nodexene, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, ZP -DI-70, TT-401 (Pegapamodtide), BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Tirzepatide (LY3298176), Bamadutide (SAR425899), Exenatide-XTEN and Glucagon-Xten.

[0111] Examples of oligonucleotides are, for example, the cholesterol-lowering antisense therapeutic mipomersen sodium (Kynamro®) for the treatment of familial hypercholesterolemia, or RG012 for the treatment of Alport Syndrome.

[0112] Examples of DPP4 inhibitors are linagliptin, vidagliptin, sitagliptin, denagliptin, saxagliptin, berberine.

[0113] Examples of hormones include pituitary or hypothalamic hormones or regulatory active peptides and their antagonists, such as gonadotropins (follitropin, lutropin, chorion gonadotropin, menotropin), somatropine (somatropin), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin, and goserelin.

[0114] Examples of polysaccharides include glycosaminoglycans, hyaluronic acid, heparin, low molecular weight heparin or very low molecular weight heparin or derivatives thereof, or sulfated polysaccharides, such as the above-mentioned polysaccharides in polysulfated form, and / or their pharma- ceutically acceptable salts. An example of a pharma-ceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F20 (Synvisc®), sodium hyaluronate.

[0115] The term "antibody" as used herein refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of an immunoglobulin molecule include F(ab) and F(ab')2 fragments that retain the ability to bind to an antigen. An antibody can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a chimeric antibody, a deimmunized or humanized antibody, a fully human antibody, a non-human (e.g., murine) antibody, or a single chain antibody. In some embodiments, an antibody has effector function and is capable of fixing complement. In some embodiments, an antibody has reduced or no binding ability to Fc receptors. For example, an antibody can be an isotype or subtype, an antibody fragment, or a mutant that does not support binding to Fc receptors, e.g., with a mutation or deletion of the Fc receptor binding region. The term antibody also includes antigen-binding molecules based on tetravalent bispecific tandem immunoglobulins (TBTI) and / or dual variable region antibody-like binding proteins (CODV) with crossover binding region orientation.

[0116] The term "fragment" or "antibody fragment" refers to a polypeptide (e.g., antibody heavy and / or light chain polypeptide) derived from an antibody polypeptide molecule that does not include the full-length antibody polypeptide but comprises at least a portion of the full-length antibody polypeptide that is still capable of binding to an antigen. An antibody fragment can include truncated portions of a full-length antibody polypeptide, but the term is not limited to such truncated fragments. Antibody fragments useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments, such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments, such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIPs), binding domain immunoglobulin fusion proteins, camelized antibodies, and VHH-containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.

[0117] The term "complementarity determining region" or "CDR" refers to short polypeptide sequences in the variable regions of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences in the variable regions of both heavy and light chain polypeptides that are not CDR sequences and are primarily responsible for maintaining the proper arrangement of the CDR sequences to allow antigen binding. Although the framework region itself typically does not directly participate in antigen binding, as is known in the art, certain residues in the framework region of a particular antibody may be directly involved in antigen binding or may affect the ability of one or more amino acids in the CDR to interact with the antigen.

[0118] Exemplary antibodies are anti-PCSK-9 mAb (eg, alirocumab), anti-IL-6 mAb (eg, sarilumab), and anti-IL-4 mAb (eg, dupilumab).

[0119] Pharmaceutically acceptable salts of any of the APIs described herein are contemplated for use in the drug or medicament in the drug delivery device. Pharmaceutically acceptable salts include, for example, acid addition salts and base salts.

[0120] Those skilled in the art will appreciate that modifications (additions and / or deletions) to the various components, formulations, devices, methods, systems, and embodiments of the API described herein may be made without departing from the full scope and spirit of the invention, which includes such modifications and all equivalents thereof.

[0121] It will be further apparent to those skilled in the art that various modifications and changes can be made to the present disclosure without departing from the scope of the present disclosure. Furthermore, it should be noted that any reference numbers used in the appended claims should not be construed as limiting the scope of the present disclosure.

[0122] In the following, an example of an injection device with an electronic unit is explained in more detail with reference to the drawings. [Brief description of the drawings]

[0123] [Figure 1] FIG. 2 shows a schematic longitudinal cross section of an example of an injection device. [Diagram 2] FIG. 2 shows a schematic diagram of the injection device according to FIG. 1, with the distal housing component decoupled from the proximal housing component. [Diagram 3] FIG. 13 shows a longitudinal section through an example of a drive mechanism implemented with an injection device. [Figure 4] FIG. 13 is an exemplary diagram showing the interaction of the electronic unit of the injection device with an external electronic device. [Diagram 5]FIG. 1 is a block diagram of an injection system including an injection device and an external electronic device. [Figure 6] FIG. 13 illustrates a distal housing component comprising an identifier. [Figure 7] FIG. 13 illustrates a distal housing component and medication container with an identifier. [Figure 8] FIG. 2 illustrates an example of an electrical identifier. [Figure 9] FIG. 13 is a diagram showing another example of an electrical identifier. [Figure 10] FIG. 13 is a diagram showing another example of an electrical identifier. [Figure 11] FIG. 1 shows a schematic representation of an implementation of an electrical sensor. [Figure 12] FIG. 2 shows two diagrams illustrating various signals of an electrical sensor. [Figure 13] 1 is a flow chart of a method for unlocking the operation of an injection device. [Figure 14] FIG. 13 is a view of the proximal end of the distal housing component. [Figure 15] FIG. 13 is a view of the distal end of the proximal housing component. [Figure 16] FIG. 16 shows a longitudinal section through the housing components of FIGS. 14 and 15 assembled together. [Figure 17] 13A-13C show an example of a label including a coil configured to be secured to one of the distal and proximal housing components. [Figure 18] 13A-13C show another example of a label including a coil configured to be secured to one of the distal and proximal housing components. [Figure 19] FIG. 19 shows the label according to FIG. 18 in a wound or coiled configuration. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0124] In Fig. 1 to Fig. 3, Fig. 6 and Fig. 7, details of an example of an injection device 10 implemented as a pen-type injector are shown in schematic form. The injection device 10 may be part of an injection system or a drug delivery system 1, as shown in Fig. 5. The injection device 10 comprises a housing 11. The housing 11 may be of elongated or tubular shape. The housing 11 extends in a longitudinal or axial direction (z). Towards the distal direction 2, the injection device 10 comprises a protective cap 6 which covers the distal housing component 12. The housing 11 further comprises a proximal housing component 14 which is removably connectable with the distal housing component 12. As becomes clear from Fig. 1, Fig. 2 and Fig. 6, the proximal housing component 14 comprises a connecting end 28 towards the distal direction 2.

[0125] The coupling end 28 of the proximal housing component 14 includes a receptacle 27 configured to receive the complementary proximal coupling end 16 of the distal housing component 12. As shown in Figures 2 and 6, the proximal coupling end 16 of the distal housing component 12 includes an insert portion 17 configured to couple with the distal coupling end 28 of the proximal housing component 14. To that end, the proximal housing component 14 includes a receptacle 27 at the distal coupling end 28 that is configured and shaped to receive the insert portion 17 therein.

[0126] The insert portion 17 has at least one fastening element 19 on its outer surface, implemented for example as a protrusion that mates or engages with a complementary recess on the inner surface of a side wall of the receptacle 27. The insert portion 17 and the receptacle 27 can include corresponding or complementary fastening elements to form a snap-fit ​​engagement, a bayonet joint, or a threaded joint.

[0127] The insert portion 17 is longitudinally limited by a radially outwardly extending flange 18. The flange 18 proximally longitudinally abuts a distal end face of the sidewall or distal end of the proximal housing component 14 when the housing components are fully assembled.

[0128] The distal housing component 12 is implemented as a cartridge holder. It includes a tubular-shaped side wall 13 configured and sized to receive a drug container 30, as shown in FIG. 7. The cartridge holder includes at least one aperture 15 in its tubular-shaped side wall 13, as shown in FIG. 7. The tubular-shaped side wall 13 tapers radially towards the distal end to form a shoulder portion adjacent the distal coupling end 20. The drug container 30 is typically filled with an injectable drug 4, for example provided or stored in liquid form inside the drug container 30.

[0129] The connecting end 20 includes a mount 21 for a needle assembly 23. The needle assembly 23 includes a needle hub 24 configured for removable or releasable engagement with the mount 21, and further includes an injection needle 25. The injection needle 25 is typically implemented as a double-ended injection needle. When properly assembled with the mount 21, the proximal tip of the injection needle 25 passes through the distal through-hole 22 of the connecting end 20 to reach and pierce a seal 35 at the distal end of a drug container 30 located inside the cartridge holder.

[0130] The seal 35 can be implemented as a rubber disk and can act as a pierceable septum. The seal 35 can be mechanically fixed to the distal end of the barrel 31 of the drug container 30 by a crimped metal cap 36. The tubular barrel 31 of the container 30 is sealed towards the proximal end by a stopper 34, implemented for example as a rubber stopper. The piston or stopper 34 is movably arranged inside the barrel 31. The piston or stopper 34 can be displaceable towards the distal direction 2, and thus towards the dosing end of the injection device 10, by the action of a piston rod 40 of a drive mechanism 8 provided and assembled inside the proximal housing component 14.

[0131] The drive mechanism 8 can be implemented in many different ways, in which case the disclosure is in no way limited to the particular example of the drive mechanism 8 currently shown. In the currently shown example, the drive mechanism 8 includes a piston rod 40 with a pressure piece 41 at its distal end. The pressure piece 41 is configured to apply distal pressure to the stopper 34 of the drug container 30. The drive mechanism or injection device further includes a housing insert 42, which serves as a mount for the multiple moving components of the drive mechanism 8.

[0132] Typically, the drive mechanism 8 includes a number sleeve 43 with consecutive sequence numbers on its outwardly facing sidewall. The numbers are visible through a window 26 or a respective aperture in the sidewall 29 of the proximal housing component 14. The drive mechanism 8 further includes a driver 44, which may be implemented as a drive sleeve. For dose setting, the number sleeve 43 typically undergoes rotation relative to the housing 11 along a first rotational direction. During dose dispensing or injection, the number sleeve 43 undergoes rotation along a second, and therefore opposite, rotational direction.

[0133] The driver 44 or drive sleeve can be operatively engaged with the piston rod 40, permanently or non-permanently. At least during dose dispensing, the driver 44 is engaged with the piston rod to transmit force or transmit torque to urge the piston rod 40 in the distal direction 2 for dose ejection or dose injection. In some implementations of the drive mechanism 8, the driver 44 undergoes rotation along a second rotational direction during dose dispensing. In some examples, the driver 44 undergoes rotation along a first rotational direction during and / or for dose setting. In some examples, the driver 44 is non-rotatably and / or axially fixed relative to the housing 11 during dose setting, but is movable during dose dispensing or dose injection.

[0134] The drive mechanism 8 further includes a dose dial 46, for example provided at the proximal end of the proximal housing component 14. The dose dial 46 provides a user-gripable or user-operable tool for dose setting. Typically, the dose dial 46 is rotatable by a user relative to the housing 11 for dose setting. The drive mechanism 8 further includes a trigger 48, for example implemented as a dose button depressible in the distal direction 2 by a user to initiate and / or control the dose dispensing or dose injection process.

[0135] The trigger 48 and the dose dial 46 can be provided on a common member. They can be integrally formed. They can both be located on a so-called dial extension of the injection device 10, which undergoes a helical movement relative to the housing 11 during dose setting and a longitudinal distal movement during and / or for dispensing or injecting a dose. Typically, the trigger 48 is provided at the proximal end of the dose dial 46. The trigger 48 can form or be constructed of a proximal end face of the housing 11.

[0136] In the example of Fig. 3, a number of possible implementations of the interlocks 90, 91, 92, 93, 97, 98, 99 are shown. Here, the interlock 90 is provided as an interlock between the trigger 48 and the dose dial 46. When the interlock 90 is activated, it can effectively block the mutual displacement of the trigger 48 relative to the dose dial 46. When the trigger 48 should be non-rotatably fastened to the housing 11 or the dial extension, the interlock 90 can also be activated to block the rotation of the dose dial 46 relative to the trigger 48 and thus relative to the housing 11. Thus, activation of the interlock 90 can effectively block or halt the dispensing of the dose and / or the dialing or setting of the dose.

[0137] The interlock 91 is mechanically coupled to the proximal housing component 14 and at least one of the dose dial 46, the trigger 48, and the dial extension. Activation of the interlock 91 serves to block or impede at least one of rotational and longitudinal sliding movement of the dose dial 46 relative to the housing component 14. When the interlock 91 is activated, it may effectively block setting of a dose and / or dispensing of a dose.

[0138] The drive mechanism 8 may further include at least a first clutch 45 and a second clutch 47. The clutches 45, 47 allow the drive mechanism 8 to be switched between a dose setting mode and a dose injection mode. Depending on the specific implementation of the drive mechanism 8, the clutches 45, 47 may be operable to engage any two of the following components with each other: the piston rod 40, the housing insert 42, the housing 11, the number sleeve 43, the driver 44, the dose dial 46, and / or the trigger 48. Details of an example of a drive mechanism are further described in document WO2014 / 033195A1. The clutch 45 may comprise a further interlock 93, and the clutch 47 may comprise an interlock 92. The interlock 92 may be operably engaged with the clutch 47. Similarly, the interlock 93 may be operably engaged with the clutch 45.

[0139] When the interlocks 92, 93 are activated, the operation of the respective clutches 47, 48 can be blocked to prevent switching of the drive mechanism 8 from the dose setting mode to the dose injection mode and / or vice versa, i.e. from the dose injection mode to the dose setting mode.

[0140] 3, the number sleeve 43 is selectively engagable with the proximal housing component 14 via an interlock 97. In a further example, the number sleeve 43 is selectively engagable with the housing insert 42 via an interlock 98. In a further example, the number sleeve 43 is selectively engagable with at least one of the dose dial 46 and the trigger 48 via another interlock 99, as shown in FIG.

[0141] Interlock 97 allows for blocking or impeding at least one of rotational and longitudinal movement of number sleeve 43 relative to proximal housing component 14. Interlock 98 allows for selectively blocking or impeding at least one of rotational and longitudinal movement of number sleeve 43 relative to housing insert 42. Because number sleeve 43 undergoes at least one of rotational, helical, or longitudinal sliding movement relative to proximal housing component 14 during dose setting and dose injection, blocking the movement of number sleeve 43, respectively, serves to block or impede at least one of the dose setting and dose injection actions.

[0142] The interlock 99 may block movement, e.g., rotational and / or longitudinal movement, of the dose dial 46 and / or trigger 48 relative to the number sleeve 43. Thus, in a typical implementation of the drive mechanism 8, the interlock 99, when activated, may at least substantially impede or prevent injection of the dose.

[0143] In a typical implementation, each of the interlocks 90, 91, 92, 93, 97, 98, 99 includes an electromechanical actuator and at least one of a latch and a clamp. Thus, the latch or clamp is movable between a locked configuration and an released configuration by the actuator, the operation of which can be controlled, for example, by electrical signals obtained from or generated by the processor 72, the functions of which are described below. Typically, the latch provided on the first component of the injection device 10 is configured for form-fit engagement with the second component of the injection device.

[0144] In other examples where the interlock includes a moveable clamp, the clamp on the first component of the injection device is configured to engage with a second component of the injection device with a friction fit. In any case, activation of the interlock 90, 91, 92, 93, 97, 98, 99 can result in a form-fit and / or frictional engagement between the first and second components of the injection device to block or prevent dose setting and / or dose dispensing.

[0145] The actuators may include electromagnets and / or electromechanical drives controllable by the processor 72. The latches, implemented for example as movable or resiliently deformable bent arms, hooks, or clamps, are movable by the actuators between a locked position in which the interlocks 90, 91, 92, 93, 97, 98, 99 are activated, and a released position in which the interlocks 90, 91, 92, 93, 97, 98, 99 are deactivated. In the deactivated configuration, the interlocks 90 and 91, 92, 93, 97, 98, 99 enable and assist movement of a first component relative to a second component of the drive mechanism to enable at least one of dose setting and dose injection.

[0146] The injection device 10 further comprises an electronic unit 70. In this example, the electronic unit 70 is embedded inside the drug delivery device 10. The electronic unit 70 is located at or near the proximal end of the housing 11. It may be located inside or disposed in a dial extension of the injection device 10. In the example shown in Figs. 3 and 4, the electronic unit 70 is located inside a hollow space of the cylindrical dose dial 46, which space is covered and / or closed in the proximal direction 3 by the trigger 48. Here, the trigger 48 provides an end cap forming a proximal closure of the hollow dose dial 46. In some examples, the trigger 48 and the dose dial 46 are integrally formed.

[0147] The electronic unit 70 includes a printed circuit board 71 that comprises a processor 72. The electronic unit 70 further comprises a source of electrical energy, typically implemented as an electric battery 73. As illustrated, the processor 72 and the battery 73 may be provided on opposite sides of the printed circuit board 71.

[0148] The electronic unit 70 is shown diagrammatically in the block diagram of FIG. 5. The electronic unit 70 further includes an interface 78 that is electrically connected to an electrical sensor 150 provided at or near the distal end of the proximal housing component 14. The electrical sensor 150 can be stationarily mounted and / or fixed on or in a sidewall of the tubular shaped proximal housing component 14. In some examples where the electronic unit 70 is movably disposed in the proximal housing component 14 or coupled to a dial extension that is movable relative to the proximal housing component, a sliding contact 77 can be provided that keeps the interface 78 in electrical contact with the electrical sensor 150. The interface 78 can be implemented as a near field communication (NFC) interface.

[0149] The electronic unit 70 may further include a communications interface, for example in the form of a short-range communications interface 76 , particularly configured to communicate with a corresponding short-range communications interface 86 of the external electronic device 80 .

[0150] The processor 72 is connected to the interlock 90 and is operable to control the operation of the interlock 90. ​​The interlock 90 may be implemented as an electromechanical interlock. The interlock 90 may include a latch or any other type of mechanically movable component to block or prevent operation of the drive mechanism 8.

[0151] Typically, the latch or movable component of the interlock 90 is movable through and by an actuator electronically controllable by the processor 72. Optionally, the electronic unit 70 comprises a sensor 74 operable to detect or measure the movement of at least one movable component 7 of the drive mechanism 8. The movable component 7 may be represented by any of the above mentioned movable components, for example the piston rod 40, the number sleeve 43, the driver 44, the trigger 48, the dose dial 46 and / or the clutches 45, 47. The sensor 74 may be implemented as one of an optical, capacitive, inductive, light or acoustic sensor and allows for managing and monitoring the operation of the drive mechanism 8 and thus the injection device 10.

[0152] Information regarding the size of the dose currently being set, dialed or dispensed may be obtained by the sensor 74 and stored in local storage 75. Data captured or acquired during repeated and subsequent uses of the injection device 10 may be stored in storage 75. Such injection-related data stored in storage 75 may be synchronized by short-range communications interface 76 with an external electronic device 80 and / or an external database 96, for example hosted or provided by a healthcare provider.

[0153] Typically, the external electronic device 80 is implemented as a smartphone, a smartwatch, or a tablet computer. The external electronic device 80 may include a long-range communication interface 88 that establishes a communication link to an external database 96 by way of a communication network 94. Typically, the external electronic device 80 is a mobile device or a wearable device. It includes a display 81 and / or a speaker 82 for communicating with a user.

[0154] Further, one of the distal housing component 12 and the drug container 30 includes an electrical identifier 50. When the distal housing component 12 is coupled or assembled with the proximal housing component 14, the electrical identifier 50 is detectable or readable by the electrical sensor 150. The electrical identifier 50 and the electrical sensor 150 can then spatially overlap without contact. In some examples, the electrical identifier 50 is provided in the insert portion 17 of the distal housing component 12, as shown in FIG. 7. Here, the electrical sensor 150 is provided on or in the side wall 29 of the proximal housing component 14. The electrical sensor 150 can be adjacent to the distal end of the proximal housing component 14 and can be disposed on or inside the receptacle 27. Thus, when the distal housing component 12 and the proximal housing component 14 are assembled with each other, for example as shown in FIG. 1, the electrical identifier 50 can be surrounded by the electrical sensor 150. The electrical identifiers 50 and electrical sensors 150 may be arranged in an interleaved or interdigitated fashion.

[0155] In the example of Figure 6, the electrical identifier 50 is located on the sidewall 13 of the distal housing component 12. It can be located on an exterior or interior surface of the insert portion 17. In the example of Figure 7, the electrical identifier 50 is located on an exterior or interior portion of the sidewall 32 of the barrel 31 of the drug container 30. Typically, the electrical identifier 50 is located at or near the proximal end of the sidewall 32 of the barrel 31. When the drug container 30 is assembled inside the distal housing component 12, the electrical identifier 50 is located in the area of ​​the insert portion 17.

[0156] As shown in Figs. 8 and 9, the electrical identifier 50 includes an inductive identifier 52, which includes a coil 54 or solenoid coil having a coil axis A extending substantially parallel to the longitudinal direction (z) of the housing 11. The inductive identifier 52 may include a levitation coil 53, i.e., an essentially closed coil. The electrical identifier 50 includes a coil 54 having a number of windings 58. In the example of Fig. 8, the coil 54 is electrically connected to a capacitor 55. In this way, the electrical identifier provides an LC circuit with a well-defined, e.g., adjustable, resonant frequency. The resonant frequency of the LC circuit can be arbitrarily changed by selecting a capacitor of an appropriate size and / or by using a coil 54 with a number of respective windings 58. In effect, the resonant frequency of the LC circuit can be changed by changing the number of windings 58 of the coil 54 by changing the capacitance of the capacitor 55.

[0157] The resonant frequency of the LC circuit may be indicative of the type of medication 4 , the size of the medication container 30 , or may be indicative of the distal housing component 12 with its respective electrical identifier 50 .

[0158] Similarly, as shown in FIG. 11, the electric sensor 150 is implemented as an inductive sensor 152. The electric sensor 150 can include a conductive coil 154. The conductive coil 154 can include a helical coil structure and can include a coil axis B extending substantially parallel to the length of the housing 11. The electric sensor 150, specifically the helical coil 154, includes a first connector 151 and a second connector 153 on either side of the helical coil 154. The coil 154 includes several helical windings 158. The connectors 151, 153 are separately connected to the interface 78 of the electronic unit 70. They can form or belong to a sliding contact 77, specifically when the electronic unit 70 or its printed circuit board 71 is to be movably arranged inside the housing 11.

[0159] In some examples, the connectors 151, 153 include conductive strips or conductive paths that extend longitudinally along, within, and / or on a component of the injection device 10. In some examples, at least one of the connectors 151, 153 extends on, along, or within at least one of the side wall 29 of the proximal housing component 14, the side wall of the housing insert 42, the side wall of the digit sleeve 43, or any other stationary or movable component of the injection device 10. In some examples where the connectors 151, 153 are disposed on, along, or within a movable component of the drive mechanism 8, a sliding contact 77 is typically also provided by which electrical signals to and from the electrical sensor 150 can be transmitted to and from the electronic unit 70 and / or its processor 72. In some examples, to detect and / or characterize the electrical identifier 50, the electrical sensor 150 can be designed to transmit at least one of a broadband (chirp) signal or a frequency ramp (sweep) signal to the electrical identifier 50 and evaluate the response or load to the electrical sensor 150 inductively coupled to the electrical identifier 50.

[0160] The transmission or excitation of the electrical identifier 50 by a swept signal is shown in Fig. 12, where the top diagram 200 shows a schematic of a frequency swept signal versus time. In the corresponding diagram 202, a sharp peak can be observed at the resonant frequency ω0, reflecting the amplitude R of the response signal versus the applied frequency. A similar or analog characteristic response can be obtained from the electrical identifier when applying a broadband frequency signal by the electrical sensor.

[0161] As further shown in FIG. 10 , the electrical identifier 50, e.g., an analog LC circuit with coil 54 or a digitally implemented microchip 56, can be provided or printed on a flat substrate 51. The flat substrate 51 can include a foil on which the conductive structures are printed. In some examples, the substrate 51 comprises an adhesive layer or adhesive substance, e.g., on the side opposite the coil 54. The adhesive or adhesive layer can permanently couple the substrate 51, and thus the entire electrical identifier, to, e.g., the distal housing component 12 and / or the barrel 31 of the container 30. In some examples, the conductive structures of the inductive identifier 52 can even be embedded or insert molded into the sidewall 13 of the distal housing component 12.

[0162] In some examples, the electrical sensor 150, and therefore the inductive sensor 152, may be provided on a flat substrate 51, for example implemented as a soft or flexible foil, which allows the electrical sensor 150 to be assembled and / or fixed on or inside the proximal housing component 14.

[0163] In the example of FIG. 9, the inductive identifier 52 comprises a microchip 56. Here, as shown in FIG. 10, the microchip 56 can include a microprocessor and an embedded local memory 57. Here, the coil 54 can act or behave as an antenna for RF communication with the electric detector 150. Here, the electric detector 150 can provide an inductive reader. The inductive identifier 52 with the microchip 56 provides digital encoding of the drug container 30 or the distal housing component 12. Here, the electric detector 150 can transmit a distinct signal with a distinct carrier frequency to trigger the microchip 56. Instead, by harvesting electromagnetic energy from an electromagnetic field provided by the electric detector 150, the microchip 56 can operate to modulate the respective coil signal, the modulation being detectable by the electric sensor 150.

[0164] The microchip 56 is configured to modulate the coil signal with digital information such that specific data relating to the medication, such as the medication name, medication manufacture date, medication expiration date, medication lot number, or a unique medication container ID, can be extracted from the electronic identifier 50 and provided to a processor 72 in the electronic unit 70.

[0165] When implemented as a passive electronic digital identifier 50, as shown in Figure 10, the identifier 50 may include a near field communication tag 59 with an antenna 55 and a microchip 56. The microchip 56 may include local storage or memory 57, for example, for storing medication-related information and / or for storing medication container-related information. The memory 57 may be implemented as a read-only memory or a re-writable memory.

[0166] In either case, the identifier 50 may include a flat substrate 51 for attaching the identifier 52 to the sidewall 13 of the distal housing component 12 or to the sidewall of the barrel 31 of the medication container 30. The flat substrate 51 may include a flexible or deformable sheet structure having an adhesive layer that adhesively attaches the substrate 51, and thus the identifier 50, to the housing component 12 or medication container 30.

[0167] The external electronic device 80 can be wirelessly paired to the electronic unit 70. Upon successful pairing, a respective confirmation can be provided to the user, for example via a display 81 and / or a speaker 82 of the external electronic device 80. Upon transfer of the data or information of the identifier 50 between the electronic unit 70 and the external electronic device 80, a visual and / or an audible confirmation can be provided to the user, for example by the electronic unit 70 and / or the external electronic device 80.

[0168] If recognition or processing of the data or information in the electronic identifier 50 indicates that the medication container 30 is intended for use with the injection device 11, the processor 72 is operable to deactivate the interlock 90, thereby allowing a dose of medication to be set and / or dispensed or injected.

[0169] The processor 72 and / or the at least one interlock 90, 91, 92, 93 can be implemented in a variety of different ways. In one approach, the interlock 90 or locking mechanism may be operable to lock the setting of a dose, lock the dispensing of a dose, and / or lock both the setting and dispensing of a dose.

[0170] The interlock 90 and / or the processor 72 can further be configured to implement, for example, an automatic relock after the respective dosing or injection procedure is finished. Furthermore, based on a signal obtainable from the sensor 74, the processor 72 can be provided with information indicative of the remaining fill level of the medicament container 30. Thus, the processor 72 can invoke activation of the interlock 92 upon providing the sensor 74 with a respective sensor signal that the medicament container 30 is substantially depleted or empty. Removal or insertion of the medicament container 30, as well as decoupling or recoupling of the housing components 12, 14, can trigger the deactivation of the automatic locking or drive mechanism for dose setting and / or dosing.

[0171] The information provided by the electrical identifier 50 and detectable, captureable or readable by the electrical sensor 150 may also provide tamper protection, where the unique code must be verified by the electronic unit 70 and / or by data exchange with or validation by the external database 96.

[0172] 13, in a first step 100, a user may place a drug container 30 with an identifier 50 inside the distal housing component 12. Thereafter, in step 102, the distal housing component 12 and the proximal housing component 14 are coupled together such that the electrical identifier 50 on one of the drug container 30 and the distal housing component 12 is in an overlapping or nested arrangement with an electrical sensor 150 on or near the distal coupling end 28 of the proximal housing component 14. Here, the coil axis A of the inductive identifier 52 may be coaxially positioned with the coil axis B of the inductive detector 152.

[0173] In the nested or spatially overlapping arrangement of the coils 54, 154, the respective coils 54, 154 remain free of mechanical contact and the coils 54, 154 are, and remain, electrically insulated from one another.

[0174] In a subsequent step 104, the processor 72 can trigger a read routine, for example by generating at least one or a series of read signals and transmitting the read signals to the electrical identifier 50 via the inductive detector 152. In response, the electrical identifier 50, including the characteristics and thus the distinct resonant frequencies, is operable to generate a respective response signal detectable by the inductive detector 152, as described above, for example with respect to FIG. 12. Inductive coupling between the mutually corresponding inductive identifiers 52 and the inductive detector 152 results in the generation of at least one detection signal by the electrical sensor 150. Such detection signal is transmitted to the electronic unit 70 via the interface 78.

[0175] Thus, based on detection signals obtainable from the inductive detector 152 in response to interaction with the conductive identifier 52, the respective detection signals may be verified by the processor 72 in step 106. The detection signals may then be compared to predefined detection signals stored, for example, in the local storage 75 of the electronic unit 70, to identify the type of electrical identifier 50 and thus the medication container 30 or distal housing component 12.

[0176] Typically, the processor 72 performs a data check and evaluates or processes the data or signals obtained from the electrical sensor 150. If the medicament container 30 is intended for use with a particular injection device 10, the respective data is approved and, in step 108, the interlock 90 is controlled or operated by the processor 72 to unlock the drive mechanism 8 of the injection device 10. The user can then start using the injection device 10 for setting a dose of medicament 4 and / or injecting the dose. In other situations, when the medicament container 30 is not intended for use with the injection device 10, the interlock 90 is triggered to block or lock the drive mechanism 8 of the injection device 10.

[0177] In the example shown in Figures 14-16, an electrical identifier 50 including a helical coil 54 is assembled or disposed on an exterior surface of the sidewall 13 of the coupling end 16 of the distal housing component 12. In the example shown, the coil 54 is disposed in the insert portion 17 of the distal housing component 12. In other examples, the coil 54 may be embedded in the sidewall 13 or may be insert molded into the sidewall 13. The helical coil 54 includes a number of windings 58. The number of windings 58 and / or the inductive response provided by the coil 54 is indicative of a particular distal housing component 12 that includes or has been provided with a particular drug.

[0178] Here, the number of windings 58 of the coil 54 and / or the inductive response serve to distinguish between multiple available distal housing components 12 and / or multiple medications or medication containers associated therewith. At least one of the number of windings 58 of the coil 54 and the inductive response, measurable and / or detectable by the electrical detector 150, can determine the presence of one of several different distal housing components 12 as well as the presence of one of the dedicated medications among several medications located inside the respective distal housing component 12.

[0179] Additionally, an electrical detector 150 is disposed on the inside surface of the sidewall 29 of the proximal housing component 14. The electrical detector 150 is disposed on or in the sidewall of the coupling end 20 of the proximal housing component 14. The electrical detector 150 includes a helically wound coil 154 having multiple windings 158. The coil 154 may be embedded inside the sidewall 29 of the proximal housing component 14 or may be insert molded into the proximal housing component 14.

[0180] The electrical detector 150 is provided on or within the receptacle 27 configured and shaped to receive the insert portion 17 of the distal housing component 12. In the final assembly configuration shown in FIG. 16, an annular gap may be provided between the coils 54 and 154. In this manner, direct electrical contact between the coils 54 and 154 may be substantially avoided. In some examples, at least one of the coils 54, 154 is embedded within the sidewall 13 of at least one of the distal housing component 12 and the proximal housing component 14. In this manner, direct electrical contact between the coils 54, 154 may be avoided even when the outer surface of the insert portion 17 is in direct mechanical contact with the inner surface of the receptacle 27. When the coils 54 and 154 are electrically insulated from each other, an exclusive inductive coupling may be provided between the coils 54, 154 as described above.

[0181] 16, the coil 54 of the electrical identifier 50 is disposed inside the coil 154 of the electrical detector 150. Such an interleaved or coaxial arrangement is beneficial for obtaining and providing inductive coupling between the coils 54 and 154, and thus between the electrical identifier 50 and the electrical detector 150.

[0182] 17-19, a further example of an electronic identifier 50 is shown that includes an inductive coil 54. Here, the coil 54 is formed by a conductor strip 63 that includes a first contact zone 62 at one longitudinal end and a second contact zone 64 at another longitudinal end, e.g. the opposite end, of the conductor strip 63. The conductor strip 63 and / or the contact zones 62, 64 may be located on a flat substrate 51, e.g. coated or printed. The flat substrate 51 may include a flat sheet. The flat substrate 51 may form or include a label 60 that is configured to be attached to one of the distal housing component 12, the proximal housing component 14, and / or the flat substrate 51 may be configured to be attached to the outer surface of the medicament container 30.

[0183] The label 60 may comprise a printed label portion 61 on which may be provided readable and / or visible information indicative of at least one of the distal housing component 12, the proximal housing component 14, or indicative of information relating to the container 30 and / or its contents. In this manner, the electronically readable electronic identifier 50 may be incorporated into the label 60, which is configured to be attached, e.g., adhesively attached, to the housing components 12, 14 of the injection device 10 or to the drug container 30 thereof.

[0184] The flat substrate 51 is soft and / or flexible. The flat substrate 51 may comprise a flexible foil that may be coiled into a wound configuration as shown in FIG. 19. The substrate 51, and thus the flexible foil, may be made from an electrically insulating material. The flat substrate 51 may comprise multiple turns or windings. In effect, the flexible foil or flat substrate 51 is configured to wind around a winding or coil axis A as shown in FIG. 17. The winding or coil axis A may coincide with a longitudinal direction z of the distal housing component 12, one of the proximal housing components 14 and the drug container 30, respectively.

[0185] As shown in Figures 17-19, the conductor strip 63 includes a first elongated conductor strip portion 65 and a second elongated conductor strip portion 67. The first conductor strip portion 65 extends at an angle relative to the second conductor strip portion 67. As shown in Figures 17-19, the second conductor strip portion 67 extends substantially parallel to the winding axis A. The first conductor strip portion 65 extends at a winding angle relative to the length of the second conductor strip portion 67, and thus relative to the winding axis A.

[0186] When the substrate 51, and therefore the label 60, is in a wound or coiled configuration having the winding axis A as its axis of symmetry, the first conductive strip portion 65 forms a helical structure, as shown in Figure 19, where the winding angle of the first conductive strip portion 65 defines the leads of the helical structure.

[0187] Typically, the conductor strip 63 is provided on one of the outwardly facing and inwardly facing surfaces of the wound substrate 51 or label 60. The contact zones 62, 64 connected to the free ends of the first and second conductor strip portions 65, 67 are therefore provided on the same side of the substrate 56 or label 60. Typically, the first contact zone 62 is connected to an end of the first conductor strip portion 65 facing away from the second conductor strip portion 67. The second contact zone 64 is connected to a free end of the second conductor strip portion 67 facing away from the first conductor strip portion 65. The end of the first conductor strip portion 65 facing away from the first contact zone 62 is therefore directly connected to the respective end of the second conductor strip portion 67 facing away from the second contact zone 64.

[0188] The first and second conductor strip portions 65, 67 may be integrally formed and may represent respective sections or portions of an integral conductor strip 63. Similarly, the contact zones 62, 64 may be integrally formed or connected with the respective first and second conductor strip portions 65, 67.

[0189] Typically, the conductor strip 63 and the contact zones 62, 64 are provided on the same side of the substrate 51. Thus, in a coiled or wound configuration, the first and second contact zones 62, 64 can at least partially or even completely overlap when viewed radially relative to the winding axis A, as shown in Fig. 19. Here, the first and second contact zones 62, 64 are electrically insulated by the electrically insulating substrate 51 located between the overlapping contact zones 62, 64.

[0190] In this way, the overlapping contact zones 62, 64 can form a capacitor 55 as shown diagrammatically in the schematic diagram of FIG. 8. The size and geometry of the contact zones 62, 64 can be individually adapted and designed to provide a capacitor 55 with a capacitance of a predetermined size. The contact zones 62, 64 are not intended to provide electrical contacts to any other components of the electronic unit 70. Compared to the geometry of the elongated conductor strip 63, the contact zones 62, 64 can include a relatively large surface area, for example of square, rectangular, round or elliptical shape. The diameter or cross section through the contact zones 62, 64 is substantially larger than the width of the elongated conductor strip.

[0191] When the frequency of the electrical drive signal is in the appropriate range to drive the electrical detector 150 which is inductively coupled to the coil 54, the coil 54 formed by the conductor strip portions 65, 67 and the overlapping contact zones 62, 64 form an LC circuit which provides a distinguishable resonant frequency and therefore an inductively measurable response.

[0192] In effect, the electrical identifier 50 is suitable for providing an inductively readable coding. Different electrical identifiers can be distinguished by the number of turns of the coil 51 and / or the different capacitances of the capacitor 55. Thus, in the example of Figures 17-19, when the contact zones 62, 64 are in an at least partially overlapping configuration, the size of the contact zones 62, 64 and the material from which the contact zones 62, 64 are made, and / or the thickness of the substrate 51 and the material of the substrate 51 can have a distinct effect on the size of the capacitance of the capacitor 55.

[0193] In some examples, the side of the substrate 51 or the label 60 opposite the side of the label 60 that includes the conductor strip 63 and / or the contact zones 62, 64 includes an adhesive, e.g., an adhesive layer, configured to attach the substrate 51 to one of the side walls of the distal housing component 12, the proximal housing component 14, or the drug container 30. In other examples, an adhesive is provided on the side of the substrate 51 that includes the conductor strip 63 and / or the side that includes the contact zones 62, 64.

[0194] Comparing the example of FIG. 17 with the example of FIG. 18, it is immediately apparent that the substrate 51′ of the label 60 of FIG. 18 is somewhat larger than the substrate 51 of the label 60 shown in FIG. 17. Here, in the example of FIG. 17, the label 60 or its label portion 61 is not configured to form multiple windings or turns. Rather, the substrate 51 shown in FIG. 17 comprises a substrate extension 51a that protrudes from a lateral edge of the generally rectangular shaped substrate 51. The shape and geometry of the substrate extension 51a closely corresponds to the geometry and shape of the first conductor strip portion 65 and the associated contact zone 62. Here, the substrate extension 51a is configured to be wound around one of the distal housing component 12, the proximal housing component 14, or the drug container 30. [Explanation of symbols]

[0195] 1. Drug Delivery Systems 2 Distal direction 3 Proximal direction 4. Drugs 6 Protective cap 7 Movable components 8 Driving mechanism 10 Injection Device 11. Housing 12 Housing Components 13 Side wall 14 Housing Components 15 Aperture 16 Connecting end 17 Insertion 18 Flange 19 Fastening Elements 20 Connecting end 21 Mount 22 Through hole 23 Needle Assembly 24 Needle Hub 25 Syringe needle 26 Windows 27 Receptacle 28 Connecting end 29 Side wall 30 containers 31 barrels 32 Side wall 34 Stopper 35 Sealing part 36 Cap 40 Piston rod 41 Pressure Components 42 Housing insert 43 Number Sleeve 44 Driver 45 Clutch 46 Dose Dial 47 Clutch 48 Trigger 50 Electrical Identifier 51 Substrate 51a Board extension 52 Guidance Identifier 53 Levitation coil 54 Coil 55 Capacitor 56 Chips 57 Memory 58 Windings 59 Near Field Communication Tags 60 Labels 61 Print label part 62 Contact Zones 63 Conductor Strip 64 Contact Zones 65 Conductor strip part 67 Conductor strip part 70 Electronic Unit 71 Printed Circuit Board 72 processors 73 Battery 74 Sensors 75 Storage 76 Short Range Communication Interface 77 Sliding Contact 78 Interface 80 External Electronic Devices 81 Display 82 Speaker 86 Short Range Communication Interface 88 Telecommunications Interface 90 Interlock 91 Interlock 92 Interlock 93 Interlock 94 Network 96 Databases 150 Electrical Detector 151 Connector 152 Induction Detector 153 Connector 154 Coil 158 Windings

Claims

1. An injection device (10) for injecting a dose of a medicament (4), comprising: The housing (11) has an elongated shape extending along a longitudinal direction (z), The housing (11) includes a distal housing component (12) and a proximal housing component (14), the distal housing component (12) configured to house a medicament container (30) and the proximal housing component (14) configured to house or support a drive mechanism (8) that operably engages the medicament container (30) to expel or draw a dose of the medicament (4) from the medicament container (30); The injection device further comprises: a drive mechanism (8) in operative engagement with the drug container (30); an electronic unit (70) coupled to the drive mechanism (8); an electrical sensor (150) disposed at or near the distal end of the proximal housing component (14), electrically connected to the electronic unit (70), and configured to contactlessly detect an electrical identifier (50) disposed on or in one of the medication container (30) and the distal housing component (12); The injection device comprising:

2. 2. The injection device (10) of claim 1, wherein the drive mechanism (8) comprises at least one interlock (90, 91, 92, 93) configured to disable at least one of dose setting and dose dispensing.

3. 3. An injection device (10) according to claim 2, wherein the electronic unit (70) is operable to control at least one interlock (90, 91, 92, 93) based on a signal received from the electrical sensor (150).

4. The injection device (10) of any one of claims 1 to 3, wherein the distal housing component (12) comprises a connecting end (16) for releasably connecting to a connecting end (28) of the proximal housing component (14).

5. 5. The injection device (10) of claim 4, wherein the electrical identifier (50) is disposed on or in one of the coupling end (16) of the distal housing component (12) and the proximal end of the medication container (30).

6. An injection device (10) according to claim 4 or 5, wherein the electrical sensor (150) is arranged on or in the coupling end (28) of the proximal housing component (14).

7. An injection device (10) according to any one of the preceding claims, wherein the electrical sensor (150) is configured for contactless detection of the presence and / or type of the electrical identifier (50).

8. An injection device (10) according to any one of claims 1 to 7, wherein the electrical identifier (50) comprises an induction coil (52) or a solenoid coil having a coil axis (A) extending substantially parallel to the longitudinal direction (z) of the housing (11).

9. The injection device (10) of claim 8, wherein the electrical identifier (50) comprises a levitation coil (53).

10. An injection device (10) as claimed in claim 8 or 9, wherein the induction coil (52) is provided on a flexible substrate (51) configured to be attached or placed on one of the tubular side walls (13, 32) of the distal housing component (12) and the drug container (30).

11. The injection device (10) according to any one of claims 8 to 10, wherein the electrical identifier (50) is encoded by at least one of: several windings (54) of the induction coil (52), a capacitor (55) electrically connected to the induction coil (52), and a microchip (56) electrically connected to the induction coil (52).

12. An injection device (10) according to any one of claims 1 to 11, wherein the electrical sensor (150) comprises an inductive coil (152) or a solenoid coil having a coil axis (B) extending substantially parallel to the longitudinal direction (z) of the housing (11).

13. An injection device (10) according to any one of the preceding claims, wherein the electrical identifier (50) comprises a passive electronic identifier (52).

14. The injection device (10) of claim 13, wherein the passive electronic identifier (52) comprises a near field communication (NFC) tag (53) configured to communicate with an electrical sensor (150) implemented as a corresponding near field communication interface (78) of the electronic unit (70).

15. The passive electronic identifier (52) comprises: Drug name, Drug manufacturing date, Drug expiration date, Drug lot number, Unique Drug Container ID 15. An injection device according to claim 13 or 14, comprising a non-volatile memory (57) for storing at least one of the following:

16. 16. An injection device according to claim 15, wherein the non-volatile memory (57) is at least one of erasable and writable by the near-field communication interface (78).

17. At least one interlock (90, 91, 92, 93) includes an electromechanical interlock configured to mechanically engage a first component (40, 42, 44) of the injection device (10) and a second component (43, 46, 48) of the injection device (10), the first component (40, 42, 44) being movable relative to the second component (43, 45, 46, 47, 48) for at least one of dose setting and dose injection.

4. An injection device (10) according to claim 2 or 3, wherein at least one interlock (90, 91, 92, 93) is operable to switch between an interlocked state in which the first component (40, 42, 44) is movably locked to the second component (43, 45, 46, 47, 48) and a released state in which the first component (40, 42, 44) is movable relative to the second component (43, 45, 46, 47, 48).

18. 18. The injection device (10) of any one of claims 1 to 17, wherein the drive mechanism (8) includes at least one clutch (45, 47) operable to switch the drive mechanism between a dose setting mode and a dose injection mode, and wherein the at least one interlock (92, 93) is operably engaged with the at least one clutch (45, 47) to selectively disable switching of the drive mechanism (8) from one of the dose setting mode and the dose injection mode to the other of the dose setting mode and the dose injection mode.

19. An injection device according to any one of the preceding claims, wherein a drug container (30) filled with a drug is arranged inside the housing (11).

20. 1. A method for unlocking the operation of an injection device (10) for at least one of setting or injecting a dose of a medication (4), the injection device (10) comprising: The housing (11) has an elongated shape extending along a longitudinal direction (z), The housing (11) includes a distal housing component (12) and a proximal housing component (14), the distal housing component (12) configured to house a medicament container (30) and the proximal housing component (14) configured to house or support a drive mechanism (8) that operably engages the medicament container (30) to expel or draw a dose of the medicament (4) from the medicament container (30); The injection device further comprises: a drive mechanism (8) in operative engagement with the drug container (30); an electronic unit (70) coupled to the drive mechanism (8); an electrical sensor (150) disposed at or near the distal end of the proximal housing component (14), electrically connected to the electronic unit (70), and configured to detect an electrical identifier (50) disposed on or in one of the medication container (30) and the distal housing component (12); At least one interlock (90, 91, 92, 93) configured to disable at least one of dose setting and dose dispensing; The method of unlocking an operation of an injection device (10) comprises: detecting, by an electrical sensor (150), at least one of the presence and type of an electrical identifier (50); generating at least one detection signal indicative of the electrical identifier (50) and transmitting said at least one detection signal to an electronic unit (70); verifying the detection signal; temporarily deactivating and / or reactivating at least one interlock (90, 91, 92, 93) based on verification of the detection signal; The method comprising:

Citation Information

Patent Citations

  • Drug delivery device and drug delivery system

    EP3669912A1

  • Method and system for determining information related to a drug reservoir using electronic sensors

    JP2013534163A

  • Modular implantable medical device

    WO2020043819A1